alexa First aid anaphylaxis management in children who were prescribed an epinephrine autoinjector device (EpiPen).
Pharmaceutical Sciences

Pharmaceutical Sciences

Journal of Developing Drugs

Author(s): Gold MS, Sainsbury R

Abstract Share this page

Abstract BACKGROUND: Epinephrine for first aid use by parents and other caregivers and in the form of an autoinjector device (EpiPen, Center Laboratories) is often prescribed for children who have had previous anaphylactic reactions. It is not known whether the EpiPen device is used appropriately during subsequent reactions and whether its use is able to prevent the complications of anaphylaxis. OBJECTIVE: Our purpose was to determine parental knowledge and practice concerning first aid anaphylaxis management, the frequency of recurrent generalized allergic reactions, the first aid measures taken, and the subsequent outcome of these reactions. METHODS: A retrospective survey was performed with a telephone questionnaire of all children with a history of anaphylaxis who attended a specialist allergy service and were prescribed an EpiPen autoinjector device. RESULTS: Recurrent generalized allergic reactions occurred with a frequency of 0.98 episodes per patient per year and were more common in those with food compared with insect venom anaphylaxis. The EpiPen device was only used in 29\% of recurrent anaphylactic reactions. Parental knowledge was deficient in recognition of the symptoms of anaphylaxis and use of the EpiPen device, and adequate first aid measures were not in place for the majority of children attending school. Those children in whom the EpiPen device was used were less likely to be given epinephrine in hospital and to require subsequent hospital admission. CONCLUSION: The EpiPen autoinjector device is infrequently used in children with recurrent episodes of anaphylaxis; the reasons for this require further research. It is likely that parents and other caregivers will require continuing education and support in first aid anaphylaxis management. When the EpiPen device is used appropriately, it appears to reduce subsequent morbidity from anaphylaxis. This article was published in J Allergy Clin Immunol and referenced in Journal of Developing Drugs

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]e.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords